The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2020-2030 period. Even though systemic targeted drugs for hepatocellular carcinoma in China are limited, with only five agents beyond surgery or chemotherapy available, the pipeline of emerging therapies is promising. We anticipate the launch and uptake of many key therapies in China—particularly the immune checkpoint inhibitors Tecentriq, Opdivo, Keytruda, Imfinzi, AiRuiKa, and Tyvyt; these key therapies will drive the hepatocellular carcinoma market over the forecast period. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing hepatocellular carcinoma market over the coming years.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of hepatocellular carcinoma in urban versus rural China. Clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma regimens through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: > 10 drugs; Phase II: > 10 drugs; Phase I/II: 7; coverage of select Phase I products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.